Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Elevidys-treated boys aged 4-7 years with Duchenne showed an increase on the North Star Ambulatory Assessment (NSAA), a measure of motor function, compared to placebo at 52 weeks but the primary...
-
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early...
-
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a...
-
Bâle, le 19 octobre 2023 Les ventes du groupe ont augmenté de 1 %1 à taux de change constants (TCC) au cours des neuf premiers mois, avec une forte augmentation de 7 % au troisième trimestreSans les...
-
Basel, 19. Oktober 2023 Konzernverkäufe steigen in den ersten neun Monaten um 1%1 zu konstanten Wechselkursen (CER), mit einem deutlichen Wachstum von 7% im dritten Quartal Konzernverkäufe ohne...
-
Basel, 19 October 2023 Group sales grow by 1%1 at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products, Group sales...
-
Neonatal sepsis is a leading cause of death for newbornsTesting IL-6 can indicate a neonatal sepsis infection earlier than other biomarkersEarlier diagnosis of neonatal sepsis can lead to improved...
-
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC) With about one in two people with...
-
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to...
-
10-year efficacy data highlight OCREVUS’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from...